Increased Risk of Pneumococcal Infections in Cardiac Transplant Recipients

Amber, Ina J.; Gilbert, Edward M.; Schiffman, Gerald; Jacobson, Jay A.

doi:10.1097/00007890-199001000-00027

Cited by 55 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, several studies have estimated the incidence of IPD among persons with high-risk conditions such as sickle-cell anemia, HIV infection, chronic pulmonary diseases, cardiac diseases, alcoholism and/or smoking [6,7,[25][26][27][28]. According to systematic reviews, anatomic or functional asplenia, immunodeficiency and immunocompromising conditions are considered as major risk factors for IPD [6,29].…”

Section: Discussionmentioning

confidence: 99%

Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Vaccination could lead to a heightened inflammatory reaction and additional lung damage in those with high antibody levels and should therefore only be considered in CF patients without protective antibodies. The latter is particularly true when lung transplantation is considered as transplant recipients might be at an increased risk of pneumococcal infection [73,74,86]. CF lung transplant recipients may also be vaccinated after transplantation.…”

Section: Streptococcus Pneumoniae Haemophilus Influenzae Neisseria mentioning

confidence: 99%

Immunisation in the current management of cystic fibrosis patients

Malfroot

Adam

Ciofu

et al. 2005

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

Although no special recommendations exist, clearly patients with cystic fibrosis (CF) can benefit from immunisation. We reviewed the literature regarding vaccination in CF and other chronic diseases. CF subjects should follow national immunisation programmes without delay to obtain optimal vaccination coverage. Indeed they may escape normal programmes due to frequent hospital admissions and school absenteeism and may be more at risk to get "vaccine-controlled" diseases at any age. There is no uniform European immunisation schedule for basic infant and childhood vaccines or for vaccines against hepatitis A (HAV) and B (HBV), varicella (VZ) and booster vaccinations. HAV and HBV vaccination is appropriate in CF as recommended in general for patients with chronic liver disease (CLD). Varicella (VZ) vaccination is not recommended in all European countries. There are no recent data about possible worsening of pulmonary status following VZ in CF, but it is known to cause pulmonary damage in non-CF adults and to be potentially fatal post transplantation and during steroid treatment. Therefore it is recommended at least for seronegative adolescents and transplant candidates. Influenza vaccine is recommended annually for CF patients aged > or =6 months. Pneumococcal vaccine is generally indicated for CF patients. RSV infection might play a role in the initial Pseudomonas colonization and the decline in pulmonary function. However no RSV vaccine is available at present. There are no recommendations for palivizumab in CF as an alternative but expensive prophylaxis. Anti-bacterial vaccinations protecting directly against Pseudomonas aeruginosa colonisation are promising for the future, potential candidates are currently being assessed in phase III clinical trials. More studies are needed to complete recommendations especially for CF adults and transplant candidates.

show abstract

“…We aimed to further characterize the antibody defect observed after HT. The clinical relevance of pneumococcal infections after solid organ transplantation, particularly in the first 2 postoperative years, has been previously documented [1]. However, studies assessing the response to pneumococcal polysaccharide immunization have not included patients within the first postoperative years (before 24 months) [3,4].…”

Section: Discussionmentioning

confidence: 99%

“…Heart transplant (HT) recipients may develop severe infections with Streptococcus pneumoniae [1]. Vaccination has been recommended in heart, renal and liver recipients.…”

Section: Introductionmentioning

confidence: 99%